(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 April 2023 (20.04.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/064366 A1

(51) International Patent Classification:
A61P 3/00 (2006.01) *C07D 487/04* (2006.01)
A61P 25/00 (2006.01) *C07D 519/00* (2006.01)
A61P 35/00 (2006.01) *A61K 31/519* (2006.01)

(21) International Application Number:
PCT/US2022/046416

(22) International Filing Date:
12 October 2022 (12.10.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/254,733 12 October 2021 (12.10.2021) US
63/347,757 01 June 2022 (01.06.2022) US

(71) Applicant: **BIOSPLICE THERAPEUTICS, INC.** [US/US]; 9360 Towne Centre Drive, San Diego, California 92121 (US).

(72) Inventors: **MITTAPALLI, Gopi Kumar**; 10416 Whitcomb Way, #99, San Diego, California 92127 (US). **KUMAR KC, Sunil**; 10504 Clasico Court, San Diego, California 92127 (US). **MAK, Chi Ching**; 11942 Caneridge Road, San Diego, California 92128 (US). **HOFILENA, Brian Joseph**; 3564 Brookshire St., San Diego, California 92111 (US). **TURNER, Lewis Daniel**; 7025 Charmant Drive, Unit 309, San Diego, California 92122 (US). **EASTMAN, Brian Walter**; 10518 Caminito Pollo, San Diego, California 92126 (US). **VAKITI, Ramkrishna Reddy**; 7699 Palmilla Dr, Apt 3316, San Diego, California 92122 (US). **MARAKOVITS, Joseph Timothy**; 2403 Summerhill Drive, Encinitas, California 92024 (US).

(74) Agent: **CULHANE, Crystal L.** et al.; P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*

WO 2023/064366 A1

(54) Title: PYRROLO[2,1-F][1,2,4]TRIAZINES DERIVATIVES AS INHIBITORS OF DYRK1A



I

(57) Abstract: Pyrrolo[2,1-f][1,2,4]triazine compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of pyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).